
|Videos|October 14, 2014
Nivolumab for the Treatment of mRCC
Author(s)Robert J. Motzer, MD
Robert J. Motzer, MD, attending physician, Memorial Sloan Kettering Cancer Center, discusses nivolumab for the treatment of metastatic renal cell carcinoma.
Advertisement
Clinical Pearls
Robert J. Motzer, MD, attending physician, Memorial Sloan Kettering Cancer Center, discusses nivolumab for the treatment of metastatic renal cell carcinoma.
- Nivolumab’s novel mechanism of action makes it potentially useful for RCC.
- Nivolumab looks promising in this space because of its durability of responses, impact on survival, and favorable safety profile.
- Nivolumab is being compared with everolimus in patients with clear cell mRCC. OS is the primary endpoint.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
2
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
3
Long-Term OMNIVORE Data Show Durable Treatment-Free Survival in RCC
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5



























